B&L to stay private for 5 years or more

Article

Bausch & Lomb (B&L) bought by Warburg Pincus last October has a long-term growth plan and will not return to the public market any time soon, said Gerry Ostrov, chief executive officer, B&L.

Rochester, NY-Bausch & Lomb (B&L) bought by Warburg Pincus last October has a long-term growth plan and will not return to the public market any time soon, said Gerry Ostrov, chief executive officer, B&L.

"Nobody has given me a specific number, but something like this is probably somewhere north of five years. Certainly, we're not talking one or two years; we are talking five-plus," Ostrov said in an interview while visiting the UK. "At some time you want to recapture the value, but it's not something I think about when I get up in the morning,

"My personal objective is to get us going at a solid double-digit growth-not immediately, but I think that is an appropriate objective," he said.

According to Ostrov, most divisions of the businesses were little affected by the economic slowdown, but laser eye surgery was suffering, since patients have to pay for procedures costing several thousand dollars out of their own pockets.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.